Compare PRAX & CPB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRAX | CPB |
|---|---|---|
| Founded | 2015 | 1869 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Packaged Foods |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1B | 6.5B |
| IPO Year | 2020 | 1994 |
| Metric | PRAX | CPB |
|---|---|---|
| Price | $263.71 | $22.79 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 15 | 18 |
| Target Price | ★ $572.13 | $26.06 |
| AVG Volume (30 Days) | 427.5K | ★ 8.7M |
| Earning Date | 05-08-2026 | 06-01-2026 |
| Dividend Yield | N/A | ★ 7.63% |
| EPS Growth | N/A | ★ 6.35 |
| EPS | N/A | ★ 1.55 |
| Revenue | N/A | ★ $10,253,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7,758.26 | $0.11 |
| P/E Ratio | ★ N/A | $14.81 |
| Revenue Growth | N/A | ★ 6.40 |
| 52 Week Low | $37.25 | $19.56 |
| 52 Week High | $366.52 | $34.18 |
| Indicator | PRAX | CPB |
|---|---|---|
| Relative Strength Index (RSI) | 39.24 | 69.68 |
| Support Level | $157.29 | $19.78 |
| Resistance Level | $342.62 | $31.86 |
| Average True Range (ATR) | 21.68 | 0.74 |
| MACD | -6.71 | 0.26 |
| Stochastic Oscillator | 20.77 | 84.59 |
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.
Over the past 150-plus years, Campbell's has evolved into a leading domestic packaged food manufacturer, with a portfolio that extends beyond its iconic red-and-white labeled canned soup. In fiscal 2025 (July year-end), snacks accounted for 43% of its revenue, followed by soup (27%), other simple meals (23%), and beverages (7%). Beyond its namesake, its brands include Pepperidge Farm, Goldfish, Snyder's of Hanover, Swanson, Pacific Foods, Prego, Pace, V8, and, most recently, Rao's (a deal that closed in 2024). Around 90% of its revenue results from the US and the remainder from Canada and Latin America.